Calavo shares dip after earnings report
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
Ventura County’s Kolibri Energy strikes formula for growth in Oklahoma oil fields
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
As working from home becomes new norm, companies look to sublease surplus space
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
Sonos leads the way in patents among region’s companies
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
Semtech shares hit two-year low after company lowers Q3 guidance
Camarillo-based Semtech produced record revenue and earnings in the second quarter of 2022, but its shares plummeted 27% the day after its earnings release after the company’s guidances for the third quarter were well below analysts’ expectations. Semtech, a semiconductor company specializing in Internet of Things applications, saw its net income increase in the second Read More →
Real Estate: Oxnard townhome development bought with $70M loan
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
Amgen reports pair of positive clinical trial results
Amgen announced positive results from clinical trials of two separate drugs in late August. On Aug. 30, the Thousand Oaks-based biotech giant said its Phase 3 trail evaluating daily oral doses of Lumakras, a treatment for non-small cell lung cancer, “met its primary endpoint of progression-free survival” and demonstrated statistically significant superiority over the current Read More →
